News for Aptose Biosciences Inc. (APTO)

Aptose Biosciences (OTC: APTOF) receives an additional $2.0 million under its $8.5 million loan agreement with Hanmi Pharmaceutical. The funding advance

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of NKGen Biotech, Inc. N

SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (

SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced that it has entered into an Interest Deferral Agreement (the 'Agreement”) with Hanmi Pharmaceutical Co., Ltd. ('Hanmi”), whereby Hanmi has agreed to further defer the interest payment due under the loan facility agreement dated August 27, 2024 (the '2024 Loan Agreement”) between Aptose and Hanmi for the period commencing December 21, 2024 and ending on March 31, 2025 from June 27, 2025 to December 31, 2025 and to defer the interest due under the 2024 Loan Agreement for the period commencing March 31, 2025 and ending on June 30, 2025 to December 31, 2025.

Aptose Biosciences (APTOF) secures a new loan agreement with Hanmi Pharmaceutical for up to US$8.5 million. The loan supports the TUSCANY Phase 1/2 clin

Aptose Biosciences (APTOF) secured a non-interest bearing short-term cash advance from CEO Dr. William G. Rice to address immediate financial obligations.

SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) ( STRO), an oncology company pioneering site-speci

**media[638568]**

**media[626065]**

**media[603728]**

**media[602839]**

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Tuesday. The Dow traded up 0.26% to 42,110.35 while the NAS...

U.S. stocks traded lower this morning, with the Dow Jones falling more than 400 points on Tuesday. Following the market opening Tuesday, the Dow traded down 1....

**media[582769]**

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include i

On March 24, 2025, Bleichroeder LP (Trades, Portfolio) executed a notable transaction involving Aptose Biosciences Inc. The firm significantly reduced its holdi

On March 19, 2025, Bleichroeder LP (Trades, Portfolio) executed a notable transaction by acquiring 3,666,667 shares of Aptose Biosciences Inc (APTO) at a traded

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (”œAptose” or the ”œCompany”) ( APTO, TSX: APS), a clinical-stage prec

Shares of Global Blue Group Holding AG GB rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 f...